TY - JOUR
T1 - A new method for the labelling of proteins with radioactive arsenic isotopes
AU - Jennewein, M.
AU - Hermanne, A.
AU - Mason, R. P.
AU - Thorpe, P. E.
AU - Rösch, F.
N1 - Funding Information:
This work was conducted with the support of a grant from the Gillson-Longenbaugh Foundation, a SPORE grant in lung cancer research, a sponsored research agreement with Peregrine Pharmaceuticals Inc (Tustin, CA), the Boehringer Ingelheim Funds for Basic Research in Biomedicine, the Deutsche Forschungsgemeinschaft (DFG-Grant Ro 985/17) and the NCI P2O PRE-ICMIC CA086334, and the European Commission (European Molecular Imaging Laboratories). Thanks to Jin He for performing the ELISA.
PY - 2006/12/20
Y1 - 2006/12/20
N2 - Radioarsenic labelled radiopharmaceuticals could be a valuable asset to positron emission tomography. In particular, the long half-lives of 72As (T1 / 2 = 26 h) and 74As (T1 / 2 = 17.8 d) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of monoclonal antibodies (mab) in tumour tissue. In this work, a new method for the labelling of proteins with various radioactive arsenic isotopes was developed. For this purpose, two proteins, namely a chimeric IgG3 monoclonal antibody, ch3G4, directed against anionic phospholipids, and Rituxan (Rituximab), were labelled as a proof of principle with no-carrier-added radioarsenic isotopes (74As and 77As). The developed labelling chemistry gives high yields (>99.9%), is reliable and could easily be transferred to automated labelling systems in a clinical environment. At least for the mab used in this work, this route of radioarsenic labelling does not affect the immunoreactivity of the product. The arsenic label stays stable for up to 72 h at the molecular mass of the monoclonal antibody, which is in particular relevant to follow the pharmacology and pharmacokinetics of the labelled mab for several days.
AB - Radioarsenic labelled radiopharmaceuticals could be a valuable asset to positron emission tomography. In particular, the long half-lives of 72As (T1 / 2 = 26 h) and 74As (T1 / 2 = 17.8 d) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of monoclonal antibodies (mab) in tumour tissue. In this work, a new method for the labelling of proteins with various radioactive arsenic isotopes was developed. For this purpose, two proteins, namely a chimeric IgG3 monoclonal antibody, ch3G4, directed against anionic phospholipids, and Rituxan (Rituximab), were labelled as a proof of principle with no-carrier-added radioarsenic isotopes (74As and 77As). The developed labelling chemistry gives high yields (>99.9%), is reliable and could easily be transferred to automated labelling systems in a clinical environment. At least for the mab used in this work, this route of radioarsenic labelling does not affect the immunoreactivity of the product. The arsenic label stays stable for up to 72 h at the molecular mass of the monoclonal antibody, which is in particular relevant to follow the pharmacology and pharmacokinetics of the labelled mab for several days.
KW - Labelled antibodies
KW - Protein labelling
KW - Radioactive arsenic
UR - http://www.scopus.com/inward/record.url?scp=33751406564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751406564&partnerID=8YFLogxK
U2 - 10.1016/j.nima.2006.08.088
DO - 10.1016/j.nima.2006.08.088
M3 - Article
AN - SCOPUS:33751406564
SN - 0168-9002
VL - 569
SP - 512
EP - 517
JO - Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
JF - Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
IS - 2 SPEC. ISS.
ER -